Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01025089 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
A Phase 2 study of Thymoma and Thymic Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 8
- Study locations
NCT01025089 is a Phase 2 study of Thymoma and Thymic Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants, below the 142-participant average among 9 other Thymoma trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 4 states.
The verdict
NCT01025089, a Phase 2 study of Thymoma and Thymic Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 8
- Study locations
Study Summary
The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. The physicians will also look at changes in genes in the tumor that may relate to the effectiveness of cetuximab
Conditions Studied
Interventions
- DRUG Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
Study Locations (8)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
- Memorial Sloan Kettering West Harrison - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering at Mercy Medical Center - Rockville Centre
- Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center - Sleepy Hollow
California
- City of Hope Medical Center - Duarte
New Jersey
- Memorial Sloan Kettering at Basking Ridge - Basking Ridge
Texas
- Md Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01025089
The ClinicalTrials.gov registry entry for NCT01025089 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 9 other Thymoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thymoma appearing as the primary indexed condition, and to 1 intervention - of which Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide is the first listed.
NCT01025089 reports 8 study locations spanning 4 distinct geographic areas - top geographies include New York, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01025089 about?
NCT01025089 is a clinical study titled "Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma". The main purpose of this study is to find out the good and the bad effects that the combination of cetuximab with the traditional chemotherapy regimen of cisplatin, doxorubicin, and cyclophosphamide has when given to patients with later stage thymoma or thymic carcinoma before surgery. The physician...
What is the current status of trial NCT01025089?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-12. Estimated completion is 2026-12.
What conditions does trial NCT01025089 study?
This clinical trial studies the following conditions: Thymoma, Thymic Carcinoma, Clinical Masaoka Stage II to IVA.
What interventions are being tested in trial NCT01025089?
The interventions under investigation include: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT01025089?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01025089 being conducted?
This trial has 8 study locations across California, New Jersey, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thymoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors
RECRUITING · Phase 2
-
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
COMPLETED · Phase 2
-
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
COMPLETED · Phase 2
-
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
RECRUITING
-
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.